Lead Discovery via Scaffold Refinement: Structure‐Guided Optimization of 1,2,4‐Triazolo[1,5‐ a ]Pyrimidines as Potent Dual EGFR/CDK‐2 Inhibitors Targeting Colorectal Carcinoma

Documenti analoghi

• Pyrimidine‐Derived Scaffolds Targeting VEGFR‐2, EGFR, and HER‐2: Synthesis, Anticancer/Immunomodulatory Evaluation, and In Silico Analysis
  di: Naglaa M. Ahmed, et al.
  Pubblicazione: (2026)
• Rational Design of Triazole Hydrazide Derivatives With Imidazo[2,1‐ b ]thiazole Scaffolds as Targeted EGFR Inhibitors in NSCLC
  di: Mohamed K. Elgohary, et al.
  Pubblicazione: (2025)
• Exploring Pyrazolo[3,4‐ b ]Pyridine and Spiro‐Oxindole Hybrids as Selective CDK2 or EGFR Inhibitors for Targeted Cancer Therapy: Design, Synthesis, and Molecular Modeling Insights
  di: Ahmed K. B. A. W. Farouk, et al.
  Pubblicazione: (2026)
• Dual‐Function Lipid‐Based Nanovector Strategy for Glioblastoma Immunotherapy: STING Activation and M1 Microglia Polarization
  di: Mohamed S. Nafie, et al.
  Pubblicazione: (2026)
• Design, Synthesis and Molecular Docking of New Thieno[2,3‑d]Pyrimidin‐4‐One Derivatives as Dual EGFR and FGFR Inhibitors
  di: Sara Sultan, et al.
  Pubblicazione: (2025)